Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 48 of 214 for:    TETRACYCLINE

The Effective Treatment of Oral Helicobacter Pylori With the Success Rate of Gastric Eradication

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01863823
Recruitment Status : Completed
First Posted : May 29, 2013
Last Update Posted : May 29, 2013
Sponsor:
Information provided by (Responsible Party):
K C Yee, Ameritek USA

Brief Summary:
  1. Gastric eradication has no effective on oral H. pylori infection.
  2. Treatment of oral infection increase success rate of eradication on stomach infection.

Condition or disease Intervention/treatment Phase
Oral Helicobacter Pylori Drug: Amoxicillin and Tetracyclines Drug: Mouth washing Phase 1 Phase 2

Detailed Description:

Objective: The present study was aimed to explore the relationship of Helicobacter pylori(H. pylori) of the oral cavity with the success rate eradication of gastric H. pylori infection.

Study Design and Setting: 202 symptomatic and 148 asymptomatic individuals were recruited and tested using Saliva H. pylori antigen tests (HPS), H. pylori flagellin (HPF), the urea breathe test (UBT) and the polymerase chain reaction (PCR) test. Test subjects also received various treatments.

We collected data of HPS, HPF , PCR and UBT before treatment on 202 symptomatic patients and 148 asymptomatic individual groups. After drug treatment, we run HPS, HPF, PCR and UBT tests. If the tests of HPS, HPF and PCR show negative that indicate success of oral H.pylori eradication. If the test of UBT show negative that indicate success of stomach H.pyloi eradication. We also compare the suceess rate of eradication on stomach infection with and without oral H. pylori infection.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 350 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Director of Research Division
Study Start Date : August 2011
Actual Primary Completion Date : September 2012
Actual Study Completion Date : September 2012

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Amoxicillin and Tetracyclines
drug treatment
Drug: Amoxicillin and Tetracyclines
202 symptomatic and 148 asymptomatic individuals were recruited and tested using Saliva H. pylori antigen tests (HPS), H. pylori flagellin (HPF), the urea breathe test (UBT) and the polymerase chain reaction (PCR) test. Test subjects also received various treatments.
Other Name: dBest

Mouth washing
Mouth washing
Drug: Mouth washing
Two time washing mouth per day
Other Name: dBest




Primary Outcome Measures :
  1. Success Rate [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Diagnostic [ Time Frame: 6 months ]

Other Outcome Measures:
  1. Agreement of diagnostic and success rate of gastric eradication [ Time Frame: 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • patients with gastrointestinal complaints

Exclusion Criteria:

  • patients who had taken any antibiotics and/or proton pump inhibitors within four weeks prior to sample collection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01863823


Locations
Layout table for location information
China
Beijing University First Hospital
Beijiang, China, 1001
Sponsors and Collaborators
Ameritek USA

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: K C Yee, Director of Research Division, Ameritek USA
ClinicalTrials.gov Identifier: NCT01863823     History of Changes
Other Study ID Numbers: AmeritekUsa
Ameritek USA ( Registry Identifier: Ameritek USA )
First Posted: May 29, 2013    Key Record Dates
Last Update Posted: May 29, 2013
Last Verified: May 2013
Keywords provided by K C Yee, Ameritek USA:
Symptomatic patients
asymptomatic individuals
clinical trial
Additional relevant MeSH terms:
Layout table for MeSH terms
Amoxicillin
Tetracycline
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action